Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
As of close of business last night, BridgeBio Pharma Inc’s stock clocked out at $47.29, down -3.65% from its previous closing price of $49.08. In other words, the price has decreased by -$3.65 from its previous closing price. On the day, 1.95 million shares were traded. BBIO stock price reached its highest trading level at $49.08 during the session, while it also had its lowest trading level at $46.81.
On July 21, 2025, Truist started tracking the stock assigning a Buy rating and target price of $66. On July 14, 2025, Jefferies started tracking the stock assigning a Buy rating and target price of $70.Jefferies initiated its Buy rating on July 14, 2025, with a $70 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Aug 21 ’25 when Trimarchi Thomas sold 42,237 shares for $49.48 per share. The transaction valued at 2,090,081 led to the insider holds 421,081 shares of the business.
Kumar Neil sold 26,156 shares of BBIO for $1,276,927 on Aug 20 ’25. The Chief Executive Officer now owns 223,090 shares after completing the transaction at $48.82 per share. On Aug 21 ’25, another insider, THOMAS TRIMARCHI, who serves as the Officer of the company, bought 42,237 shares for $49.48 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BBIO now has a Market Capitalization of 9040381952 and an Enterprise Value of 10151273472. For the stock, the TTM Price-to-Sale (P/S) ratio is 38.34. Its current Enterprise Value per Revenue stands at 43.048 whereas that against EBITDA is -16.275.
Stock Price History:
The Beta on a monthly basis for BBIO is 1.25, which has changed by 0.89311445 over the last 52 weeks, in comparison to a change of 0.14460516 over the same period for the S&P500. Over the past 52 weeks, BBIO has reached a high of $51.86, while it has fallen to a 52-week low of $21.72. The 50-Day Moving Average of the stock is 2.92%, while the 200-Day Moving Average is calculated to be 32.48%.
Shares Statistics:
It appears that BBIO traded 2.88M shares on average per day over the past three months and 2055810 shares per day over the past ten days. A total of 191.16M shares are outstanding, with a floating share count of 162.09M. Insiders hold about 15.21% of the company’s shares, while institutions hold 89.34% stake in the company. Shares short for BBIO as of 1753920000 were 18519082 with a Short Ratio of 6.43, compared to 1751241600 on 21834552. Therefore, it implies a Short% of Shares Outstanding of 18519082 and a Short% of Float of 16.259999999999998.
Earnings Estimates
Investors are eagerly awaiting the insights provided by 4.0 analysts currently analyzing and rating the stock of BridgeBio Pharma Inc (BBIO).The consensus estimate for the next quarter is -$0.71, with high estimates of -$0.31 and low estimates of -$0.94.
Analysts are recommending an EPS of between -$2.1 and -$3.82 for the fiscal current year, implying an average EPS of -$2.59. EPS for the following year is -$1.58, with 6.0 analysts recommending between -$0.97 and -$2.22.
Revenue Estimates
In the current quarter, 17 analysts expect revenue to total $109.29M. It ranges from a high estimate of $140.5M to a low estimate of $85.72M. As of the current estimate, BridgeBio Pharma Inc’s year-ago sales were $2.73MFor the next quarter, 17 analysts are estimating revenue of $127.52M. There is a high estimate of $177M for the next quarter, whereas the lowest estimate is $52.37M.
A total of 20 analysts have provided revenue estimates for BBIO’s current fiscal year. The highest revenue estimate was $545.13M, while the lowest revenue estimate was $412.03M, resulting in an average revenue estimate of $473.05M. In the same quarter a year ago, actual revenue was $221.9MBased on 19 analysts’ estimates, the company’s revenue will be $771.05M in the next fiscal year. The high estimate is $1.12B and the low estimate is $536.11M.
